Taiwan · Delayed Price · Currency is TWD Bioray Biotech Statistics
Total Valuation
Bioray Biotech has a market cap or net worth of TWD 605.02 million. The enterprise value is 566.79 million.
| Market Cap | 605.02M |
| Enterprise Value | 566.79M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Aug 25, 2026 |
Share Statistics
Bioray Biotech has 29.59 million shares outstanding. The number of shares has increased by 0.05% in one year.
| Current Share Class | 29.59M |
| Shares Outstanding | 29.59M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | -0.12% |
| Owned by Insiders (%) | 11.21% |
| Owned by Institutions (%) | n/a |
| Float | 13.60M |
Valuation Ratios
The trailing PE ratio is 31.54.
| PE Ratio | 31.54 |
| Forward PE | n/a |
| PS Ratio | 2.92 |
| PB Ratio | 1.40 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | 9.51 |
| P/OCF Ratio | 9.48 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.33, with an EV/FCF ratio of 8.91.
| EV / Earnings | 29.55 |
| EV / Sales | 2.74 |
| EV / EBITDA | 13.33 |
| EV / EBIT | 28.08 |
| EV / FCF | 8.91 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.16.
| Current Ratio | 4.73 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 1.67 |
| Debt / FCF | 1.12 |
| Interest Coverage | 27.69 |
Financial Efficiency
Return on equity (ROE) is 4.40% and return on invested capital (ROIC) is 4.02%.
| Return on Equity (ROE) | 4.40% |
| Return on Assets (ROA) | 2.32% |
| Return on Invested Capital (ROIC) | 4.02% |
| Return on Capital Employed (ROCE) | 4.08% |
| Weighted Average Cost of Capital (WACC) | 4.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.38 |
| Inventory Turnover | 2.04 |
Taxes
In the past 12 months, Bioray Biotech has paid 5.34 million in taxes.
| Income Tax | 5.34M |
| Effective Tax Rate | 21.78% |
Stock Price Statistics
The stock price has decreased by -24.92% in the last 52 weeks. The beta is 0.08, so Bioray Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | -24.92% |
| 50-Day Moving Average | 18.40 |
| 200-Day Moving Average | 20.82 |
| Relative Strength Index (RSI) | 57.80 |
| Average Volume (20 Days) | 32,381 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bioray Biotech had revenue of TWD 207.17 million and earned 19.18 million in profits. Earnings per share was 0.65.
| Revenue | 207.17M |
| Gross Profit | 84.85M |
| Operating Income | 20.18M |
| Pretax Income | 24.52M |
| Net Income | 19.18M |
| EBITDA | 34.03M |
| EBIT | 20.18M |
| Earnings Per Share (EPS) | 0.65 |
Balance Sheet
The company has 109.21 million in cash and 70.98 million in debt, with a net cash position of 38.23 million or 1.29 per share.
| Cash & Cash Equivalents | 109.21M |
| Total Debt | 70.98M |
| Net Cash | 38.23M |
| Net Cash Per Share | 1.29 |
| Equity (Book Value) | 431.07M |
| Book Value Per Share | 14.57 |
| Working Capital | 259.94M |
Cash Flow
In the last 12 months, operating cash flow was 63.85 million and capital expenditures -225,000, giving a free cash flow of 63.63 million.
| Operating Cash Flow | 63.85M |
| Capital Expenditures | -225,000 |
| Depreciation & Amortization | 13.85M |
| Net Borrowing | -9.72M |
| Free Cash Flow | 63.63M |
| FCF Per Share | 2.15 |
Margins
Gross margin is 40.96%, with operating and profit margins of 9.74% and 9.26%.
| Gross Margin | 40.96% |
| Operating Margin | 9.74% |
| Pretax Margin | 11.84% |
| Profit Margin | 9.26% |
| EBITDA Margin | 16.43% |
| EBIT Margin | 9.74% |
| FCF Margin | 30.71% |
Dividends & Yields
This stock pays an annual dividend of 0.95, which amounts to a dividend yield of 5.81%.
| Dividend Per Share | 0.95 |
| Dividend Yield | 5.81% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | 5.76% |
| Earnings Yield | 3.17% |
| FCF Yield | 10.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Bioray Biotech has an Altman Z-Score of 4.12 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.12 |
| Piotroski F-Score | 4 |